Iantrek Hits 2,000 Procedures for New Bio-Interventional Technology - AlloFlo Uveo

Iantrek announced it has surpassed 2,000 AlloFlo Uveo procedures in the US. The key milestone comes ahead of its full commercial launch planned for this fall during the American Academy of Ophthalmology 2025 meeting.

Recent momentum has been fueled by the publication of 2-year safety and efficacy data and the American Academy of Ophthalmology's new reimbursement endorsement for cyclodialysis with scleral reinforcement, which the company says solidifies the clinical and economic foundation for widespread adoption.

“I’m incredibly excited to see the momentum building around AlloFlo Uveo,” Adam Szaronos, CEO of Iantrek, said in a company news release. “This innovation is a much overdue solution to a material science challenge—using natural homologous biologic tissue to reinforce a critical outflow pathway largely untapped in the interventional glaucoma treatment paradigm. Surgeons are embracing this as a solution that may help millions of glaucoma patients who are experiencing waning efficacy following canal-based MIGS.”

AlloFlo Uveo is part of Iantrek’s proprietary Allo platform and is designed to enhance the uveoscleral outflow pathway through scleral reinforcement following controlled cyclodialysis. As the first homologous, bio-conforming solution engineered for uveoscleral outflow enhancement, AlloFlo Uveo offers a hardware-free, naturally-derived bio-tissue solution for patients suffering from glaucoma.